Literature DB >> 18653164

Alzheimer's disease: a review of the disease, its epidemiology and economic impact.

K Alloul1, L Sauriol, W Kennedy, C Laurier, G Tessier, S Novosel, A Contandriopoulos.   

Abstract

This article consists of a critical review of Canadian, American and European studies published between 1976 and 1997 on the subject of Alzheimer's disease (AD), and its epidemiology, patterns of care, prognostic factors, and economic impact. As the population ages in North America and Europe, significant increases in the prevalence of AD over the next decades have been projected. The elderly population represents the largest consumer group of health care resources and the management of common diseases occurring in this population will have major medical, social, and economic implications. As a result, researchers will need to integrate the ever-increasing knowledge on AD when addressing governmental and societal concerns regarding its impact. Described herein is the study findings, limitations, and differences observed following the review of the diagnostic criteria, prevalence rates, incidence rates and risk factors. Highlighted are the areas where data is lacking. To refine current models of disease progression, and better address where health care resources and new therapies would be most beneficial, the review of predictors of institutionalization and predictive models of disease progression and survival, was performed. New research questions are indicated.

Entities:  

Year:  1998        PMID: 18653164     DOI: 10.1016/s0167-4943(98)00116-2

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  8 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.

Authors:  Jacqueline Hofrichter; Markus Krohn; Toni Schumacher; Cathleen Lange; Björn Feistel; Bernd Walbroel; Hans-Jochen Heinze; Sara Crockett; Timothy F Sharbel; Jens Pahnke
Journal:  Curr Alzheimer Res       Date:  2013-12       Impact factor: 3.498

3.  Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients.

Authors:  Sun-Ho Han; Jun Seok Kim; Youngju Lee; Heesun Choi; Jong-Won Kim; Duk Lyul Na; Eun Gyeong Yang; Myeong-Hee Yu; Daehee Hwang; Cheolju Lee; Inhee Mook-Jung
Journal:  Mol Cell Proteomics       Date:  2013-12-08       Impact factor: 5.911

4.  Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease.

Authors:  Tingxiang Yan; Luwen Wang; Ju Gao; Sandra L Siedlak; Mikayla L Huntley; Pichet Termsarasab; George Perry; Shu G Chen; Xinglong Wang
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

6.  Validation of the Thai QOL-AD version in Alzheimer's patients and caregivers.

Authors:  Nopporn Buasi; Unchalee Permsuwan
Journal:  Australas Med J       Date:  2014-06-30

Review 7.  Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease.

Authors:  Gregory A Jicha; Sarah A Carr
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

Authors:  Carlos Spuch; Carmen Navarro
Journal:  J Drug Deliv       Date:  2011-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.